A growing body of evidence suggests that the targeting of transcription factors holds promise as a therapeutic strategy for cancer. In this study, we have identified EGR1 as a transcription factor target in HCC. Our findings indicate that EGR1 expression is downregulated in HCC and that EGR1 ...
Moreover, the CSS holds promise as a robust indicator for evaluating immune cell infiltration and express levels of immune checkpoint molecules, as well as distinguishing patients responsive to immune checkpoint therapy (ICT). This molecular biomarker significantly advances our understanding of the ...